SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

22 May 2025 Evaluate
The sales is pegged at Rs. 5559.58 millions for the March 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 6029.47 millions during the year-ago period.A big loss of -79.54% reported for the quarter ended March 2025 to Rs. 161.28  millions from Rs. 788.44 millions.Operating Profit reported a sharp decline to 800.54 millions from 1370.64 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 5559.58 6029.47 -7.79 21394.23 18661.17 14.65 21394.23 18661.17 14.65
Other Income 121.22 256.47 -52.74 461.88 587.11 -21.33 461.88 587.11 -21.33
PBIDT 800.54 1370.64 -41.59 3086.30 2092.16 47.52 3086.30 2092.16 47.52
Interest 293.60 390.50 -24.81 1459.12 1393.77 4.69 1459.12 1393.77 4.69
PBDT 506.94 979.40 -48.24 1626.91 644.74 152.34 1626.91 644.74 152.34
Depreciation 223.71 219.24 2.04 846.08 874.07 -3.20 846.08 874.07 -3.20
PBT 283.23 760.16 -62.74 780.83 -229.33 -440.48 780.83 -229.33 -440.48
TAX 121.95 -28.28 -531.22 189.27 13.42 1310.36 189.27 13.42 1310.36
Deferred Tax 174.31 -1.26 -13934.13 203.91 14.61 1295.69 203.91 14.61 1295.69
PAT 161.28 788.44 -79.54 591.56 -242.75 -343.69 591.56 -242.75 -343.69
Equity 921.63 919.00 0.29 921.63 919.00 0.29 921.63 919.00 0.29
PBIDTM(%) 14.40 22.73 -36.66 14.43 11.21 28.67 14.43 11.21 28.67

Strides Pharma Scien Share Price

1070.90 69.10 (6.90%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×